{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037597","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.724480+00:00","generated_at":"2026-06-12T08:33:51.407899+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Intellia Q2 net loss $123.7M; advances CRISPR pipeline with Phase 2 enrollment for NTLA-2002 completed","bullets":["Cash, equivalents and securities $1.1B at June 30, 2023, down from $1.3B at Dec 31, 2022.","Net loss $123.7M in Q2 2023 vs $100.7M in Q2 2022; R&D expenses rose to $115.3M.","All patients identified for NTLA-2002 Phase 2 study; pivotal Phase 3 planned for Q3 2024.","NTLA-2001 IND submission for ATTR-CM expected in September; global pivotal study targeted by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037597","json":"https://secwatch.observer/filing/0000950170-23-037597.json","markdown":"https://secwatch.observer/filing/0000950170-23-037597.md","text":"https://secwatch.observer/filing/0000950170-23-037597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017023037597/0000950170-23-037597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017023037597/ntla-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:33:51.407899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1467c0b3581cf7877fe6507259f30d7e83467595","claim":"Intellia Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017023037597/0000950170-23-037597-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}